AnaSpec Introduces Thirty-Eight New Catalog Peptides

PRLog (Press Release) – Mar 19, 2008 – This week AnaSpec, one of the world’s largest providers of custom and catalog peptides, introduced thirty-eight (38) new catalog peptides.

Ubiquitin (65-76); (Ub2)
OV-3; sheep
Serorphin; BSA (399-404)
Pyrrhocoricin
Bik BH3 (50-70)
Bid BH3 (79-99)
Amphoterin (150–183)
BRCAA1 (610-619)
[Gln340]-Maspin; Reactive Site Loop (RSL); (330-345)
[-4]pPSA
p53 (17-26); FITC labeled
MAGE-3 (161-169)
S1P1
Rabies Virus Matrix Protein Fragment (RV-MAT)
Cytochrome P450 4A (431-445); rat
Elastin-Like Octapeptide
Leptin (116-130); mouse
CLIP (86-100)
CLIP (88–99)
LCMV (166-173); GP166
Lactoferroxin C; Lactoferrin (673-679)
Myosin H Chain Fragment; mice
Erythropoietin; Human (hEPO) Fragment
OVA (327-333)
Serum Albumin (102-226)
Insulin B (13-23)
Elution (EY) Peptide
DAM1 [221-241] peptide
ZIPK (264-276)
ZIPK (309-327)
FceRI gamma-chain ITAM-Derived Phosphopeptide; TAMRA labeled
Glycogen Synthase Derived Peptide; biotinylated
[pSer119]-CREB327 (113-122)
[pSer133; Leu123]-CREBtide Peptide Substrate; LC; Biotinylated
WRW4; Formyl Peptide Receptor-Like 1 (FPRL1) Antagonist
Hanatoxin
Delta-Toxin (1-26); Staphylococcus aureus
Delta-Toxin (5-20); Staphylococcus aureus

Company Info
AnaSpec, Inc. is a leading provider of integrated proteomics solutions to pharmaceutical, biotech, and academic research institutions throughout the world. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and combinatorial chemistry. Established in 1993, AnaSpec's headquarters and manufacturing facilities are located in San Jose, CA.

For more information visit www.anaspec.com